[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527924":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":39,"responsibleParty":63,"collaborators":11,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":11,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},{"fullName":5,"class":6},"Fundacion Dexeus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Follitropin-delta 20 mcg\u002Fday from D1","EXPERIMENTAL",null,[13],"Drug: Follitropin-delta (Rekovelle) 20 mcg\u002Fday from D1",{"label":15,"type":16,"description":11,"interventionNames":17},"Follitropin-delta 15 mcg\u002Fday from D1","ACTIVE_COMPARATOR",[18],"Drug: Follitropin-delta (Rekovelle) 15 mcg\u002Fday from D1",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Follitropin-delta (Rekovelle) 20 mcg\u002Fday from D1","On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Follitropin-delta (Rekovelle) 15 mcg\u002Fday from D1","On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Nikolaos P Polyzos, MD, PhD","CONTACT","0034932274700","nikpol@dexeus.com",{"name":36,"role":32,"phone":33,"phoneExt":37,"email":38},"Ignacio Rodríguez, MSc","22029","nacrod@dexeus.com",[40],{"facility":41,"status":42,"city":43,"state":11,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Hospital Universitario Quiron Dexeus","RECRUITING","Barcelona","08028","Spain","ES",{"type":48,"coordinates":49},"Point",[50,51],2.15899,41.38879,{"lat":51,"lon":50},[54,56,58,60],{"name":55,"role":32,"phone":33,"phoneExt":11,"email":34},"Nikolaos P Polyzos, MD PhD",{"name":57,"role":32,"phone":33,"phoneExt":11,"email":38},"Ignacio Rodriguez, MSc",{"name":55,"role":59,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":61,"role":62,"phone":11,"phoneExt":11,"email":11},"Valeria Donno, MD","SUB_INVESTIGATOR",{"type":64,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100527924","phase-4-intensity-of-ovarian-stimualtion-and-euploid-embryos-100527924",false,"NCT06154083","INtensity of OVarian Stimualtion and Euploid Embryos","The Impact of Ovarian Stimulation Intensity on Embryo Euploidy in Advanced Age Women","INOVEE","Inclusion Criteria:\n\n* Infertile patients with indication for IVF\n* Undergoing preimplantation genetic screening cycles\n* AMH \\>= 1.5 ng\u002Fml and \\\u003C 3.5 ng\u002Fml (AMH result of up to one year will be valid)\n* BMI 18.5 - 30 Kg\u002Fm2\n\nExclusion Criteria:\n\n* Severe male factor requiring TESE (testicular sperm extraction)\n* AMH \\\u003C 1.5 ng\u002Fml or \\>= 3.5 ng\u002Fml\n* Administration of any other drug potentially interfering with the treatment\n* Contraindication for hormonal treatment\n* Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment).\n* Monogenic disease to be detected with PGT-M","FEMALE","38 Years","42 Years",{"count":77,"type":78},110,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","This randomized trial was designed as a no-inferiority trial aiming to evaluate if the intensity of stimulation (a milder vs a more intense approach) may have an impact on the number of euploid embryos and the morpho kinetic parameters in advanced age women undergoing PGT-A with a PPOS protocol.",[84],"Fertility","2025-02-25",{"date":87,"type":88},"2025-02-27","ACTUAL",{"date":90,"type":88},"2023-12-12",{"date":92,"type":78},"2026-05-15",{"name":94,"class":6},"Fundación Santiago Dexeus Font",1]